Literature DB >> 29807805

Auditory steady state response deficits are associated with symptom severity and poor functioning in patients with psychotic disorder.

Tian-Hang Zhou1, Nora E Mueller2, Kevin M Spencer3, Sonal G Mallya4, Kathryn Eve Lewandowski4, Lesley A Norris4, Deborah L Levy5, Bruce M Cohen6, Dost Öngür4, Mei-Hua Hall7.   

Abstract

OBJECTIVES: Gamma oscillation is important for cortico-cortical coordination and the integration of information across neural networks. The 40 Hz auditory steady-state response (ASSR), which reflects neural synchrony in the gamma band (30-100 Hz), is abnormal in patients with schizophrenia (SZ). The present study used the ASSR at multiple frequencies to examine (1) gamma dysfunction in patients with SZ, schizoaffective (SA), and bipolar disorder (BD) compared with controls, (2) the relationship between ASSR measures and clinical symptom severity, and (3) the relationship between ASSR measures and real-life community functioning.
METHODS: EEG was recorded from 75 controls, 52 SZ, 55 SA, and 89 BD patients during 20-30-40-Hz binaural click trains. ANCOVA was used to compare ASSR measures between groups controlling for age, sex, and education. Associations between ASSR measures, symptom severity, and community functioning were examined using linear regression and Pearson partial correlations.
RESULTS: ASSR deficits at gamma frequency were observed in all patient groups. SA patients showed additional specific deficit in the 20 Hz ASSR. Severity of manic, depressive, and anxiety symptoms mediated ASSR deficits. Severity of hallucinatory symptom and community functioning, particularly independent living/meaningful activity, were significantly and independently associated with the 40 Hz ASSR.
CONCLUSIONS: SZ, SA and BD patients are likely to share the same abnormalities in neural processes that generate gamma oscillations. 40 Hz ASSR are associated with community functioning across patients and may serve as a biomarker for predicting functional outcome.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Affective psychosis; Community functioning; Cortical oscillation; Schizophrenia; Symptom severity

Mesh:

Year:  2018        PMID: 29807805      PMCID: PMC7003536          DOI: 10.1016/j.schres.2018.05.027

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  53 in total

1.  Stimulus induced desynchronization of human auditory 40-Hz steady-state responses.

Authors:  B Ross; A T Herdman; C Pantev
Journal:  J Neurophysiol       Date:  2005-08-17       Impact factor: 2.714

Review 2.  Functional connectivity analysis in magnetoencephalography.

Authors:  Alfons Schnitzler; Joachim Gross
Journal:  Int Rev Neurobiol       Date:  2005       Impact factor: 3.230

3.  Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia.

Authors:  Kenji Kirihara; Anthony J Rissling; Neal R Swerdlow; David L Braff; Gregory A Light
Journal:  Biol Psychiatry       Date:  2012-02-22       Impact factor: 13.382

Review 4.  The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations.

Authors:  N C Andreasen
Journal:  Br J Psychiatry Suppl       Date:  1989-11

Review 5.  Neurophysiological findings in patients with bipolar disorder.

Authors:  Toshiaki Onitsuka; Naoya Oribe; Shigenobu Kanba
Journal:  Suppl Clin Neurophysiol       Date:  2013

6.  Differentiation between major depressive disorder and bipolar disorder by auditory steady-state responses.

Authors:  Shuichi Isomura; Toshiaki Onitsuka; Rikako Tsuchimoto; Itta Nakamura; Shogo Hirano; Yuko Oda; Naoya Oribe; Yoji Hirano; Takefumi Ueno; Shigenobu Kanba
Journal:  J Affect Disord       Date:  2015-11-26       Impact factor: 4.839

7.  Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia.

Authors:  Michael J Minzenberg; Alana J Firl; Jong H Yoon; Glenn C Gomes; Celeste Reinking; Cameron S Carter
Journal:  Neuropsychopharmacology       Date:  2010-09-08       Impact factor: 7.853

8.  Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains.

Authors:  E Fuller Torrey; Beata M Barci; Maree J Webster; John J Bartko; James H Meador-Woodruff; Michael B Knable
Journal:  Biol Psychiatry       Date:  2005-02-01       Impact factor: 13.382

Review 9.  Human auditory steady-state responses.

Authors:  Terence W Picton; M Sasha John; Andrew Dimitrijevic; David Purcell
Journal:  Int J Audiol       Date:  2003-06       Impact factor: 2.117

Review 10.  Steady state responses: electrophysiological assessment of sensory function in schizophrenia.

Authors:  Colleen A Brenner; Giri P Krishnan; Jenifer L Vohs; Woo-Young Ahn; William P Hetrick; Sandra L Morzorati; Brian F O'Donnell
Journal:  Schizophr Bull       Date:  2009-09-02       Impact factor: 9.306

View more
  12 in total

1.  Auditory steady-state EEG response across the schizo-bipolar spectrum.

Authors:  David A Parker; Jordan P Hamm; Jennifer E McDowell; Sarah K Keedy; Elliot S Gershon; Elena I Ivleva; Godfrey D Pearlson; Matcheri S Keshavan; Carol A Tamminga; John A Sweeney; Brett A Clementz
Journal:  Schizophr Res       Date:  2019-05-09       Impact factor: 4.939

2.  Non-rapid eye movement sleep and wake neurophysiology in schizophrenia.

Authors:  Nataliia Kozhemiako; Jun Wang; Chenguang Jiang; Zhenhe Zhou; Wei Zhu; Mei-Hua Hal; Shaun M Purcell; Jen Q Pan; Lei A Wang; Guanchen Gai; Kai Zou; Zhe Wang; Xiaoman Yu; Lin Zhou; Shen Li; Zhenglin Guo; Robert Law; James Coleman; Dimitrios Mylonas; Lu Shen; Guoqiang Wang; Shuping Tan; Shengying Qin; Hailiang Huang; Michael Murphy; Robert Stickgold; Dara Manoach
Journal:  Elife       Date:  2022-05-17       Impact factor: 8.713

3.  Evaluating delay of gamma oscillations in patients with schizophrenia using evoked response audiometry system.

Authors:  Masaya Yanagi; Aki Tsuchiya; Fumiharu Hosomi; Toru Terada; Satoshi Ozaki; Osamu Shirakawa; Mamoru Hashimoto
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

4.  Identifying Clinically and Functionally Distinct Groups Among Healthy Controls and First Episode Psychosis Patients by Clustering on EEG Patterns.

Authors:  Xiaodong Qu; Saran Liukasemsarn; Jingxuan Tu; Amy Higgins; Timothy J Hickey; Mei-Hua Hall
Journal:  Front Psychiatry       Date:  2020-09-18       Impact factor: 4.157

5.  Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia.

Authors:  Maju Mathew Koola; Samir Kumar Praharaj; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2019-05-17

6.  Longitudinal relationships between mismatch negativity, cognitive performance, and real-world functioning in early psychosis.

Authors:  Amy Higgins; Kathryn Eve Lewandowski; Saran Liukasemsarn; Mei-Hua Hall
Journal:  Schizophr Res       Date:  2021-02-04       Impact factor: 4.939

7.  Test-retest reliability of time-frequency measures of auditory steady-state responses in patients with schizophrenia and healthy controls.

Authors:  Brian J Roach; Deepak Cyril D'Souza; Judith M Ford; Daniel H Mathalon
Journal:  Neuroimage Clin       Date:  2019-06-05       Impact factor: 4.881

8.  Gamma oscillations predict pro-cognitive and clinical response to auditory-based cognitive training in schizophrenia.

Authors:  Juan L Molina; Michael L Thomas; Yash B Joshi; William C Hochberger; Daisuke Koshiyama; John A Nungaray; Lauren Cardoso; Joyce Sprock; David L Braff; Neal R Swerdlow; Gregory A Light
Journal:  Transl Psychiatry       Date:  2020-11-23       Impact factor: 6.222

9.  Aberrant Auditory Steady-State Response of Awake Mice Induced by Chronic Interferon-α Treatment.

Authors:  Yingzhuo Li; Xuejiao Wang; Jingyu Chen; Zijie Li; Pingting Yang; Ling Qin
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

Review 10.  Gamma-Range Auditory Steady-State Responses and Cognitive Performance: A Systematic Review.

Authors:  Vykinta Parciauskaite; Jovana Bjekic; Inga Griskova-Bulanova
Journal:  Brain Sci       Date:  2021-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.